Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Oct 2017 Status changed from recruiting to discontinued.
- 03 Dec 2014 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov.